Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.

British Journal of Clinical Pharmacology
Philip George DrennanStephen Thomas Chambers

Abstract

Oral flucloxacillin may be coadministered with probenecid to reduce flucloxacillin clearance and increase attainment of pharmacokinetic-pharmacodynamic (PK/PD) targets. The aims of this study were to develop a population PK model of free flucloxacillin when administered orally with probenecid, and to identify optimal dosing regimens for this combination. We performed a prospective observational study of adults (45 participants) treated with oral flucloxacillin 1000 mg and probenecid 500 mg 8-hourly for proven or probable staphylococcal infections. Steady-state mid-dose-interval flucloxacillin measurements (45 concentrations) were combined with existing data from a crossover study of healthy participants receiving flucloxacillin with and without probenecid (11 participants, 363 concentrations). We developed a population pharmacokinetic model of free flucloxacillin concentrations within Monolix, and used Monte Carlo simulation to explore optimal dosing regimens to attain PK/PD targets proposed in the literature (free drug time above minimum inhibitory concentration). Flucloxacillin disposition was best described by a 1-compartment model with a lag time and first-order absorption. Free flucloxacillin clearance depended on probenec...Continue Reading

References

Nov 1, 1979·British Journal of Clinical Pharmacology·P G WellingR Wise
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Mar 1, 1981·Clinical Pharmacokinetics·R F CunninghamP G Dayton
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J D Turnidge
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M Lindsay GraysonFran Chambers
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Atsushi EnomotoHitoshi Endou
Sep 24, 2005·Clinical Pharmacokinetics·Sarayut JanmahasatianBruce Green
Aug 10, 2007·American Journal of Physiology. Renal Physiology·Adam L VanwertDouglas H Sweet
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 10, 2012·Therapeutic Drug Monitoring·Anneke C DijkmansJacobus Burggraaf
Dec 10, 2015·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators
Feb 5, 2016·CPT: Pharmacometrics & Systems Pharmacology·W WangD A James
Jun 10, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Fanuel T HagosPhilip E Empey
Nov 4, 2016·Pharmaceutical Research·Marc Lavielle, Benjamin Ribba
Dec 8, 2017·The Journal of Antimicrobial Chemotherapy·Johan W MoutonJohn Turnidge
Aug 29, 2018·The New England Journal of Medicine·Kasper IversenHenning Bundgaard
Jan 31, 2019·The New England Journal of Medicine·Ho-Kwong LiUNKNOWN OVIVA Trial Collaborators
Feb 6, 2020·Antimicrobial Agents and Chemotherapy·Olivia Bupha-IntrMax Bloomfield
Mar 3, 2020·Journal of Bone and Joint Infection·Helga Preissİlker Uçkay
Aug 30, 2020·Journal of Orthopaedic Surgery and Research·Øystein Espeland KarlsenMarianne Westberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Drug and Therapeutics Bulletin
Journal of Clinical Pathology
J Cook, W J Fincham
Journal of Clinical Pathology
S Hughes, F Anderson
The Australian Nurses' Journal
© 2021 Meta ULC. All rights reserved